NCT06435936View on ClinicalTrials.gov

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions

PHA1A

Interventions

DRUG

Single Ascending Dose of SAB-176

Single ascending dose

DRUG

Single Ascending Dose of Placebo

Single ascending dose

Trial Locations (1)

20889

Naval Medical Research Command (NMRC), Bethesda

All Listed Sponsors

lead

SAb Biotherapeutics, Inc.

INDUSTRY

NCT06435936 - A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo | Biotech Hunter | Biotech Hunter